Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 7, 2000, Pages 597-605

  Brooks, Robert R ^a   Finch, Susan L ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Antiarrhythmic agents; Azimilide, dog, effect on hemodynamics, fibrillation threshold; CAS 149888 94 8; Sotalol

Indexed keywords

AZIMILIDE; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOG; DOSE RESPONSE; EXCITABILITY; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CONTRACTILE FORCE; HEART OUTPUT; HEART PERFORMANCE; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE FIBRILLATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN;

EID: 0033928455     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300257     Document Type: Article

References (26)

1. [1] Francis, G. S., Should Asymptomatic Ventricular Arrhythmias in Patients with Congestive Heart Failure be Treated with Antiarrhythmic Drugs? I. Introduction. J. Am. Coll. Cardiol. 12, 274 (1988)
2. [2] Bigger, J. T. Jr., Why Patients with Congestive Heart Failure Die: Arrhythmias and Sudden Cardiac Death. Circulation 75, IV28 (1987)
3. [3] Pratt, C. M., Eaton, T., Francis, M. et al., The Inverse Relationship Between Baseline Left Ventricular Ejection Fraction and Outcome of Antiarrhythmic Therapy: A Dangerous Imbalance in the Risk-Benefit Ratio. Am. Heart J. 118, 433 (1989)
4. [4] Ravid, S., Podrid, P. J., Lampert, S. et al., Congestive Heart Failure Induced by Six of the Newer Antiarrhythmic Drugs. J. Am. Coll. Cardiol. 14, 1326 (1989)
5. [5] Lange, H., Lampert, S., Sutton, M. S. et al., Changes in Cardiac Output Determined by Continuous-Wave Doppler Echocardiography During Propafenone or Mexiletine Drug Testing. Am. J. Cardiol. 65, 458 (1990)
6. [6] Busch, A. E., Malloy, K. J., Varnum, M. D. et al., A Slowly-Activating Potassium Current IKs is the Target for the Class III Antiarrhythmic Drug NE-10064 (abstr.). Circulation 88, I-231 (1993)
7. [7] Fermini, B., Jurkiewicz, N. K., Jow, B. et al., Use-Dependent Effects of the Class III Antiarrhythmic Agent NE-10064 (Azimilide) on Cardiac Repolarization: Block of Delayed Rectifier Potassium and L-Type Calcium Currents. J. Cardiovasc. Pharmacol. 26, 259 (1995)
8. [8] Brooks, R. R., Carpenter, J. F., Miller, K. E. et al., Efficacy of the Class III Antiarrhythmic Agent Azimilide in Rodent Models of Ventricular Arrhythmia. Proc. Soc. Exp. Biol. Med. 212, 84 (1996)
9. [9] Drexler, A. P., Micklas, J. M., Brooks, R. R., Suppression of Inducible Ventricular Arrhythmias by Intravenous Azimilide in Dogs with Previous Myocardial Infarction. J. Cardiovasc. Pharmacol. 28, 848 (1996)
10. [10] Black, S. C., Butterfield, J. L., Lucchesi, B. R., Protection Against Programmed Electrical Stimulation-Induced Ventricular Tachyarrhythmia and Sudden Death by NE-10064, a Class III Antiarrhythmic Drug. J. Cardiovasc. Pharmacol. 22, 810 (1993)
11. [11] Restivo, M., Hegazy, M., Caref, E. B. et al., Effects of Azimilide Dihydrochloride on Circus Movement Atrial Flutter in the Canine Sterile Pericarditis Model. J. Cardiovasc. Electrophysiol. 7, 612 (1996)
12. [12] Pinto, J. B., Boyden, P. A., Wit, A. L. et al., The Effects of a Class III Antiarrhythmic Agent NE-10064 Which Blocks the Slowly Activating Delayed Rectifier Current (IKs) on Canine Atrial Flutter (abstr.). PACE 17, 777 (1994)
13. [13] Nattel, S., Liu, L., St-Georges, D., Effects of the Novel Antiarrhythmic Agent Azimilide on Experimental Atrial Fibrillation and Atrial Electrophysiologic Properties. Cardiovasc. Res. 37, 627 (1998)
14. [14] Salata, J. J., Brooks, R. R., Pharmacology of Azimilide Dihydrochloride (NE-10064). Cardiovasc. Drug Rev. 15, 137 (1997)
15. [15] Pritchett, E., Page, R., Connolly, S. et al., Azimilide Treatment of Atrial Fibrillation (abstr). Circulation 17, I-633 (1998)
16. [16] Page, R. L., Connolly, S. J., Marcello, S. R. et al., Dose Response for Azimilide Treatment of Paroxysmal Supraventricular Tachycardia (abstr.). PACE 44, 770 (1999)
17. [17] Brooks, R. R., Butterfield, J. L., The Class III Antiarrhythmic NE-10064 Increases QTc Interval with Minor Hemodynamic Effects in Anesthetized Dogs (abstr.). Can. J. Physiol. Pharmacol. 72, 79 (1994)
18. [18] Drexler, A. P., McCulloch, J. D., Jorgensen, R. L. et al., Simple Relationship Between Intravenous Dose, Plasma Concentration and Class III Effects of Azimilide in Conscious Dogs (abstr.). FASEB J. 11, A493 (1997)
19. [19] Joly, J. M., Manwaring, J. D., Drexler, A. P. et al., Evaluation of the Pharmacokinetics/Pharmacodynamics of Azimilide Dihydrochloride (NE-10064) in Conscious Dogs (abstr). Pharmacologist 39, 33 (1997)
20. [20] Abdollah, H., Brennan, F. J., Jimmo, S. et al., Relationship Between Myocardial Amiodarone Concentration and Antiarrhythmic Effect in Dogs with Myocardial Infarction and Electrically Induced Ventricular Arrhythmias. Can. J. Physiol. Pharmacol. 69, 812 (1991)
21. [21] Patterson, E., Lynch, J., Lucchesi, B. R., Antiarrhythmic and Antifibrillatory Actions of the Beta Adrenergic Receptor Antagonist, dl-Sotalol. J. Pharmacol. Exp. Ther. 230, 519 (1984)
22. [22] Lynch, J. J., Heaney, L. A., Wallace, A. A. et al., Suppression of Lethal Ischemic Ventricular Arrhythmias by the Class III Agent E4031 in a Canine Model of Previous Myocardial Infarction. J. Cardiovasc. Pharmacol. 15, 764 (1990)
23. [23] Restivo, M., Hegazy, M., El-Hamamy, M. et al., Antiarrhythmic Efficacy of Azimilide Dihydrochloride on Functional Circus Movement Atrial Flutter in the Canine Right Atrial Enlargement Model (abstr.). PACE 19, 664 (1996)
24. [24] Tande, P. M., Refsum, H., Class III Antiarrhythmic Action Linked with Positive Inotropy: Effects of the d-and 1-Isomer of Sotalol on Isolated Rat Atria at Threshold and Suprathreshold Stimulation. Pharmacol. Toxicol. 62, 272 (1988)
25. [25] Platou, E. S., Refsum, H., Hotvedt, R., Class III Antiarrhythmic Action Linked with Positive Inotropy: Antiarrhythmic Electrophysiological and Hemodynamic Effects of the Sea-Anemone Polypeptide ATX II in the Dog Heart in situ. J. Cardiovasc. Pharmacol. 8, 459 (1986)
26. [26] Morad, M., Trautwein, W., The Effect of the Duration of the Action Potential on Contraction in the Mammalian Heart Muscle. Pflügers Arch. 299, 66 (1968)